A novel HPβCD-Cu(DDC)<sub>2</sub> delivery system in patient derived orthotopic xenograft targeting MGMT-mediated temozolomide resistance in glioblastoma.
Ontology highlight
ABSTRACT: The uniform lethality of glioblastoma (GBM) with a survival of less than 2 years despite best available therapy is attributed to treatment resistance due to DNA repair mechanisms that drive disease relapse and tumor heterogeneity. One prognostic factor identified as a reliable biomarker for GBM sensitivity to temozolomide (TMZ) and radiotherapy (RT) is the overexpression of O6-methylguanine-methyl-transferase (MGMT) enzyme. Patients with active MGMT were found to receive little benefit from TMZ and RT. They represent a group of great unmet need with no treatment options that significantly improve survival. Recently, several preclinical and clinical studies suggest that the alcohol aversion drug, disulfiram (DSF), inhibited MGMT and improved the efficacy of TMZ in GBM when combin
SUBMITTER: Suhail H
PROVIDER: S-EPMC12464313 | biostudies-literature | 2025 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA
